paratracheal (stations 2 and 4) and subcarinal (station 7) lymph nodes can be biopsied. Extend ed MS or VATS allows to reach also preaortic (5) and aortopulmonary window (6) lymph nodes, while TBNA allows to obtain samples from sta tions 2, 4, and 7. Both ultrasound methods (ei ther EBUSTBNA or EUSFNA) allow the endos copist to access stations 2, 4, and 7, except right paratracheal stations 2R and 4R, which are not ac cessible for EUSFNA. Additionally, hilar (station 10), interlobar (station 11), and lobar (station 12) lymph nodes can be reached only by EBUSTBNA, and paraesophageal (station 8) and pulmonary ligament (station 9) lymph nodes exclusively by EUSFNA. In our study, the 3 biopsy techniques share the diagnostic area of stations 2, 4, and 7, which can be verified by MS.
This randomized study was designed to com pare the diagnostic yield of TBNA with that of EBUSTBNA and EUSFNA, with the use of 21/22gauge cytological needles, in patients clin ically and radiologically suspected of sarcoidosis with mediastinal and hilar lymphadenopathy.
PATIENTS AND METHODS Study design
This randomized controlled singlecenter, openlabel study was conducted over a period of 1 year, since January 2012 to February 2013. The study was approved by the Ethics Committee of the Jagi ellonian University in Kraków, and written in formed consent was obtained from all patients.
The study was performed at the Endoscopy Unit and Department of Thoracic Surgery at John Paul II Hospital, Jagiellonian University, Kraków, Poland.
The study included a group of consecutive pa tients meeting the following inclusion criteria: age of 18 years or older; suspicion of sarcoidosis at radiological assessment, especially that based on highresolution computed tomography, is sup ported by histological evidence of noncaseating epithelioid cell granulomas. 5 According to cur rent recommendations, diagnostic workup should include conventional bronchoscopy with endo bronchial biopsy and transbronchial lung biop sy (TBLB). However, TBLB involves the risk of pneumothorax and hemoptysis and is not used as a standard technique in stage I. If the diagnosis of sarcoidosis is not confirmed by bronchoscopic findings, more invasive surgical procedures such as mediastinoscopy (MS) or videoassisted tho racic surgery (VATS) lung biopsy may be required. MS is associated with the best diagnostic yield for stages I and II of sarcoidosis. 6 However, risk and cost-benefit analyses and the development of minimally invasive endoscopic procedures such as conventional (standard) transbronchial nee dle aspiration (TBNA) and endoscopic ultrasound techniques such as endobronchial and endoscopic ultrasoundguided fine needle aspiration (EBUS TBNA and EUSFNA, respectively) have marked ly decreased the use of MS in this setting. [6] [7] [8] [9] [10] [11] [12] [13] [14] En dosonography was introduced into clinical prac tice after numerous studies and showed excellent results in lung cancer staging and very promis ing results in sarcoidosis. [13] [14] [15] [16] [17] [18] However, it is un known which of the following minimally invasive endoscopic techniques-TBNA, EBUSTBNA, and EUSFNA-could be the method of choice in pa tients suspected of stage I or II sarcoidosis and what would be its sensitivity, specificity, accura cy, positive predictive value (PPV), and negative predictive value (NPV).
Importantly, biopsy techniques presented above have not exactly the same range of lymph node stations for biopsy access. Using MS, FIGURE 1 Endobronchial ultrasound--guided transbronchial needle aspiration imaging of right paratracheal nodes in sarcoidosis and 6.3mm wide and had 2.0mm and 2.2mm working channels, respectively, and the oblique optical system of 35º. The 7.5 MHz EUC60 and 512MHz EUME1 ultrasound processors were used, enabling tissue imaging at a depth of 20-50 mm. For biopsy, a cytological 40mm 22gauge needle with a guide wire and marking facilitat ing its ultrasound visualization was used (NA 201SX4022, Olympus Medical Systems Corpora tion). All the biopsies were performed through the macroscopically normal bronchial wall (FIGURE 1).
In the EUSFNA group, when standard vid eo bronchoscopy was finished, the patient was turned over to his or her left side, and intravenous sedation was added if necessary. EUSFNA was performed using GFUCT160OL5 video gastro scope (Olympus Medical Systems Corporation). The gastroscope's diameter was 14.6 mm, and it had the working channel of 3.7, optical system of 55º, and EUC60 7.5 MHz ultrasound proces sor, enabling tissue imaging at a depth of 20 to 50 mm (FIGURE 2). For biopsy, a cytological 80mm 22gauge needle with a guide wire and marking facilitating its ultrasound visualization was used (NA200H8022, Olympus Medical Systems Cor poration). EBUSTBNA and EUSFNA of lymph nodes of 5 mm or higher on the short axis were performed. The cytological smear of all biopsies was performed and fixed using ethanol (96%). The standard hematoxylin-eosin staining was used. Rapid onsite cytological evaluation was not performed. Samples from each lymph node station were placed separately and were reviewed by 2 clinical and research pathologists who were blinded to the sampling method.
All patients with negative TBNA or EBUSTBNA results underwent EUSFNA and those with neg ative EUSFNA results underwent EBUSTBNA.
clinical stage I or II; enlarged mediastinal lymph nodes on computed tomography (short axis ≥10 mm); and the general condition allowing to per form MS, VATS, and TBLB.
The exclusion criteria were as follows: lack of patient's consent, a history of a bleeding disorder that could not be corrected, and sarcoidosis treat ment using systemic corticosteroids and lasting more than 30 days before endoscopy.
Patients were randomized at the time of stan dard bronchoscopy to undergo conventional TBNA using 21/22gauge needles or EBUSTBNA or EUSFNA using 22gauge needles as a method additional to other bronchoscopy procedures. In each patient, 1 to 3 nodal stations were punctured and 3 to 5 passes were performed at each site.
All procedures were performed by 3 experi enced endoscopists under local anesthesia and in travenous conscious sedation (fentanyl, 0.05-0.1 mg; midazolam, 1-5 mg).
In the TBNA group, the BF 1T180 video bron choscope (Olympus Medical Systems Corpora tion, Tokyo, Japan) with the working channel of 3.0mm was used. The biopsy was performed us ing the MW122 (22gauge/13 mm) or the SW121 (21gauge/15 mm) cytological needles (Conmed Endoscopic Technologies, Utica, United States) or the NA411D1521 (21gauge/15 mm) (Olym pus Medical Systems Corporation). All the biop sies were performed through the macroscopical ly normal bronchial wall. The preferred method of the biopsy was the pushing technique.
In the EBUSTBNA group, after standard bron choscopy, EBUSTBNA was performed using the BFUC160FOL8 and BFUC180F video broncho scopes (Olympus Medical Systems Corporation), and intravenous sedation was added if necessary. The ultrasound videobronchoscopes were 6.9mm the diagnostic values of different medical tests. Additionally, 2sided uncorrected χ 2 test was used to compare the diagnostic yield of the 3 methods on the perpatient basis. The level of significance was set at a P value of 0.05 or less.
RESULTS A total of 108 patients were enrolled to this singlecenter study, of whom 8 were ex cluded. The data of 100 patients suspected of sar coidosis were included in the final analysis. The primary outcome was the diagnostic yield for de tecting noncaseating granulomas in 96% of the patients with the final diagnosis of sarcoid osis.
If the results of both biopsy techniques were neg ative, patients with stage I sarcoidosis were then scheduled for MS and those with stage II sarcoid osis-for TBLB. The material from all biopsies was also cultured for tuberculosis. All patients were reevaluated during a 6month followup (FIGURE 3).
Statistical analysis The sensitivity, specificity, ac curacy, PPV, and NPV (including 95% confidence interval) were calculated using the GraphPad In Stat 3.05 software (GraphPad Software, United States). The bootstrap method was used (using Statistica TM [Statsoft, United States]) to compare In 14 patients with negative results of stan dard TBNA and in 7 patients with negative results of EBUSTBNA, EUSFNA was performed, while in 5 patients with negative results of EUSFNA, EBUSTBNA was performed as the second proce dure. Among them, EUSFNA was positive in 9 pa tients and EBUSTBNA-in none. In 17 patients with negative biopsy results, MS was performed in 6 patients, and sarcoidosis was confirmed in 2. In the remaining 11 patients, sarcoidosis was confirmed by TBLB. None of the patients required VATS lung biopsy.
A total of 164 mediastinal and hilar nodal sta tions were biopsied: subcarinal (7), 98; lower right paratracheal (4R), 16; lower left paratracheal (4L), 10; right hilar (10R), 20; left hilar (10L), 16; and paraoesophageal (8), 4. The majority of the biop sies (60%) were performed in station 7.
Additional outcome measures included the diagnostic yield of the 3 methods calculated on the per lymphnode basis. When analyzed on the perbiopsy basis, significant differences be tween endosonography and TBNA in the diagnos tic yield in mediastinal stations were observed, and no differences were revealed if mediastinal and hilar lymph node stations were biopsied by each method alone (TABLE 4) .
No serious complications of any biopsy meth od were observed. A small bleeding at biopsy sites was not considered a complication. In 3 patients (2 after EBUSTBNA and 1 after EUSFNA), nau sea was observed, most probably due to conscious sedation. There were no readmissions to the hos pital due to pain or dysphagia for pain or dyspha gia after EUSFNA.
DISCUSSION A substantial body of data indi cate that conventional TBNA allows to diagnose stage I or II sarcoidosis during initial broncho scopic assessment, although the method relies on "blind" needle puncture guided only by com puted tomography and is highly operatordepen dent. Endosonography has become a standard technique showing high diagnostic yield for the diagnosis and staging of lung cancer, but its role in the diagnosis of sarcoidosis has not been clear ly defined.
7,11,14,15 EBUSTBNA and EUSFNA are There were 44 women and 56 men at a mean age of 43.7 ±13.1 years (range, 22-71 years). The major symptoms were cough (27%), fever (24%), articular pain (17%), and mild dyspnea (10%), but most of the patients were asymptomatic. Four teen patients were current smokers. None of the patients had received sarcoidosis treatment with systemic corticosteroids for longer than 30 days before the endoscopy. The general condition of the patients allowed to perform endoscopic lung and mediastinal biopsy under mild sedation. In the study group, 5 patients had arterial hyper tension; 4 patients, ischemic heart disease; and 2 patients, diabetes. There was no significant dif ference between the groups (TABLE 1) .
In 100 patients, 34 standard TBNA, 30 EBUSTBNA, and 36 EUSFNA procedures were performed at baseline. The main study outcome measure of the diagnostic yield was 20 positive results for 34 TBNA procedures (58.8%) com pared with 23 positive results for 30 EBUSTBNA procedures (76.7%), and 31 positive results for 36 EUSFNA procedures (86.1%), which means an absolute increase between the EBUSTBNA and TBNA groups of 17.9% (P = 0.129) and be tween the EUSFNA and TBNA groups of 27.3% (P = 0.01). The diagnostic sensitivity and accura cy of TBNA in comparison with EBUSTBNA and EUSFNA calculated on the perpatient basis were 62.5% and 64.7%, 79.3% and 80%, and 88.6% and 88.9%, respectively. The main outcome measures including the diagnostic yield of all methods per patient are presented in TABLE 2. The sensitivity and accuracy of EUSFNA were significantly high er compared with those of standard TBNA (P = endosonographic methods over standard TBNA, demonstrating a significant increase in the diag nostic yield for EUSFNA and a nonsignificant in crease for EBUSTBNA. It also showed a signif icantly higher sensitivity and accuracy of EUS FNA compared with standard TBNA (P = 0.012). Moreover, a positive tendency was observed in higher sensitivity and accuracy of EBUSTBNA compared with standard TBNA, which is consis tent with other reports. 19, 20, 24 No significant dif ferences between the sensitivity and accuracy of EUSFNA and EBUSTBNA were observed, and additional studies on a higher number of patients are necessary to compare the diagnostic yield be tween both techniques. When analyzed on the perbiopsy basis, there were significant differences between EUSFNA and TBNA. As recommended, we performed 3 to 5 passes with standard TBNA for each station, and, although there are no recommendations for EBUSTBNA and EUSFNA, we also performed 3 to 5 passes with endosonographic methods, which might have resulted in an increased diag nostic yield on the per lymphnode basis. 16, 17, 20, 28 No differences were observed when any of the sta tions was biopsied by each method alone, which may be caused by the systemic character of gran ulomatous disease.
In all patients, the diagnosis was confirmed by the cytological and histological examination. Moreover, the patients were reviewed by an ex pert clinician 6 months after the biopsy was per formed. Of 21 patients with negative TBNA and EBUSTBNA results, sarcoidosis was diagnosed in 9 by EUSFNA, but none of the 5 patients with negative EUSFNA results had the diagnosis con firmed by EBUSTBNA. This makes EUSFNA a possible referral method for transbronchial tech niques. MS was performed in 6 patients and reac tive benign nodes were found in 4. It resulted in a small number of true negative patients, which is related to the strict inclusion criteria specify ing that sarcoidosis is mainly based on clinical and radiological features. This also might have resulted in low and hardly reliable NPV. No spe cific diagnosis other than sarcoidosis was con firmed by endoscopies, MS, and TBLB or during clinical followup. No complications were not ed after biopsies (a small bleeding at biopsy site was not treated as a complication) or after con scious sedation. minimally invasive techniques by which medias tinal and hilar lymph nodes can be aspirated un der realtime ultrasound control from either the esophagus or large airways. Studies on the di agnostic value of both endosonographic meth ods showed their high yield in the diagnosis of sarcoidosis. 13, 14 There are only a few randomized controlled studies showing the superiority of EBUSTBNA over standard TBNA 19, 20 and over routine bronchoscopic techniques including en dobronchial and transbronchial lung biopsy. 21 Only 2 small prospective studies reported a sig nificantly higher yield for EBUSTBNA (85%-94%) compared with TBLB (31%-37%) to detect granulomas. 22, 23 It has not been established so far which of the techniques should be the method of choice in pul monary sarcoidosis. Our study is novel because we compared 3 biopsy methods including EUSFNA, which is rarely used by pulmonologists in the di agnosis of mediastinal adenopathy.
With the growing experience of pathologists, the demonstration of noncaseating epithelioid granulomas based on cytological material is fea sible and reliable.
9,13,24 Some authors point out the necessity for obtaining histological core tis sue biopsies with a 19gauge needle because his tological evaluation is more reliable in the exclu sion of lymphoproliferative disorders and tuber culosis (currently 19gauge needles are available only for TBNA and EUS). 25, 26 In our study, we compared cytological biop sies using 21/22gauge needles, which makes the results more reliable. The results present ed separately for all biopsy techniques (TBNA, 58.8%; EBUSTBNA, 76.7%; and EUSFNA, 86.1%) are consistent with other reports (TBNA, 46%-78%; EBUSTBNA, 82%-93%; and EUS FNA, 82%-100%). 13, 14, 24, 25, 27 This prospective randomized study confirmed the superiority of Abbreviations: see FIGURE 3 and TABLE 2 
